Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
74-79-3
Molecular formula
C6H14N4O2
Molecular weight
174.2 g/mol
Drug class
Proteinogenic amino acidurea-cycle intermediate and nitric-oxide precursor
Mechanism of action
Serves as a substrate for nitric oxide synthase, producing nitric oxide, and as an intermediate in the urea cycle. In urea-cycle disorders, exogenous arginine can support nitrogen disposal by promoting formation of ornithine and downstream urea-cycle intermediates, depending on the specific enzyme defect.
Indications / reported uses
Adjunctive management of selected urea-cycle disorders, including acute hyperammonaemia and chronic management, using formulation- and defect-specific regimens.
Used in selected mitochondrial disease presentations, including MELAS, under specialist clinical management.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for L Arginine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the L Arginine Permitted Daily Exposure (PDE) report (the L Arginine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the L Arginine Occupational Exposure Limit (OEL) report (the L Arginine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.